Inspire Medical Systems (NYSE:INSP) Rating Increased to Strong Sell at UBS Group

UBS Group upgraded shares of Inspire Medical Systems (NYSE:INSP) to a strong sell rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on INSP. Evercore downgraded shares of Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 target price for the company. in a research report on Tuesday, June 23rd. Oppenheimer reaffirmed a “market perform” rating on shares of Inspire Medical Systems in a research report on Monday, June 15th. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Wells Fargo & Company lowered their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a report on Tuesday, May 5th. Finally, Summit Redstone set a $39.00 price objective on Inspire Medical Systems in a research note on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $73.28.

Inspire Medical Systems Trading Up 2.0%

INSP stock opened at $51.93 on Tuesday. The firm has a 50 day simple moving average of $45.61 and a 200-day simple moving average of $56.43. The company has a market capitalization of $1.50 billion, a P/E ratio of 11.57, a PEG ratio of 5.16 and a beta of 0.71. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The firm had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. During the same period in the prior year, the company posted $0.10 earnings per share. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, research analysts predict that Inspire Medical Systems will post 0.93 EPS for the current year.

Institutional Trading of Inspire Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of INSP. Wellington Management Group LLP acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at about $203,929,000. Wasatch Advisors LP raised its stake in Inspire Medical Systems by 7.2% during the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after acquiring an additional 110,288 shares during the period. Morgan Stanley raised its stake in Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after acquiring an additional 809,121 shares during the period. Deerfield Management Company L.P. lifted its holdings in Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after acquiring an additional 907,694 shares during the last quarter. Finally, State Street Corp lifted its holdings in Inspire Medical Systems by 2.3% in the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after acquiring an additional 22,843 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.